Partner Headlines - BMRN

  1. BioMarin Weathers The Storm

    Benzinga
  2. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  3. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  4. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  5. Benzinga's Top Upgrades

    Benzinga
  6. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  7. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  8. Top Trending Tickers On StockTwits For February 18

    Benzinga
  9. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  10. You Can No Longer Ignore Biotech

    GuruFocus
  11. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  12. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  13. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  14. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  15. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  16. Benzinga's Top #PreMarket Gainers

    Benzinga
  17. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  18. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  19. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  20. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  21. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  22. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  23. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  24. Roche

    IBD
  25. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  26. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  27. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  28. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  29. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  30. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  31. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  32. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  33. Benzinga's Volume Movers

    Benzinga
  34. Benzinga's Top Pre-Market Gainers

    Benzinga
  35. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  36. Benzinga's Top Pre-Market Gainers

    Benzinga
  37. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  38. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  39. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  40. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  41. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  42. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  43. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  44. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  45. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  46. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  47. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  48. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  49. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  50. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  51. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  52. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  53. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  54. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  55. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  56. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  57. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  58. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  59. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  60. BioMarin soars on drug data

    IBD
  61. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  62. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  63. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
  64. Stocks Hitting 52-Week Highs

    Benzinga
  65. BioMarin Stock Soars On Positive Drug Data

    IBD
  66. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga
  67. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  68. BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q)

    GuruFocus
  69. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  70. UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical ...

    Benzinga
  71. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  72. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  73. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  74. Health Care Sector Wrap

    FoxBusiness
  75. Benzinga's Top Downgrades

    Benzinga
  76. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  77. BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ ...

    Benzinga
  78. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  79. BioMarin Pharmaceutical, Health Net Among Stocks Up on High Volume ...

    FoxBusiness
  80. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  81. Amylin Pharmaceuticals, Constellation Brands Among Stocks Setting ...

    FoxBusiness
  82. Analyst Initiations: BMRN, FB, and MDVN

    SchaeffersResearch
  83. Benzinga's Top Pre-Market Gainers

    Benzinga
  84. From Earlier: Wedbush Reiterates BioMarin Pharmaceuticals Neutral, ...

    Benzinga
  85. Benzinga's Morning Initiation Summary for June 1, 2012

    Benzinga
  86. BioMarin Pharmaceutical (BMRN) Loses 7.2% After Pricing Offering ...

    MarketIntelligenceCenter
  87. BioMarin Announces Pricing of Public Offering of Common Stock; ...

    Benzinga
  88. UPDATE: Citi Raises BioMarin Pharmaceuticals' PT

    Benzinga
  89. BioMarin Pharmaceutical (BMRN) Loses 1.3% as Volatility Continues

    MarketIntelligenceCenter
  90. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  91. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  92. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  93. BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper ...

    GuruFocus
  94. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  95. Upgrades & Downgrades: YHOO, BMRN, HGSI, DNDN, and TSLA

    SchaeffersResearch
  96. Just What The Doctor Ordered: 4 ETFs For Biotech M&A

    Benzinga
  97. BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper ...

    GuruFocus
  98. Stocks at New Highs: BioMarin Pharmaceutical and Seattle Genetics

    SchaeffersResearch
  99. Call Volume Spikes on BioMarin Pharmaceutical

    SchaeffersResearch
Trading Center